Gordon Van Slyke: A Trial Participant’s Inside Look at New Alzheimer’s Drug Leqembi
When Gordon Van Slyke, 75, decided to participate in the phase drug trials for Eisai and Biogen’s new monoclonal antibody drug Leqembi (lecanemab), it was his family history with Alzheimer’s that motivated him.
Read more about his story:
https://www.beingpatient.com/lecanemab-leqembi-trial-participant-story/
Create your
podcast in
minutes
It is Free